These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 27745709)

  • 1. Coming-of-Age of Antibodies in Cancer Therapeutics.
    Ayyar BV; Arora S; O'Kennedy R
    Trends Pharmacol Sci; 2016 Dec; 37(12):1009-1028. PubMed ID: 27745709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic bispecific antibody formats: a patent applications review (1994-2017).
    Godar M; de Haard H; Blanchetot C; Rasser J
    Expert Opin Ther Pat; 2018 Mar; 28(3):251-276. PubMed ID: 29366356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody-drug conjugates and bispecific antibodies targeting cancers: applications of click chemistry.
    Hong Y; Nam SM; Moon A
    Arch Pharm Res; 2023 Mar; 46(3):131-148. PubMed ID: 36877356
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The next generation of antibody drug conjugates.
    Mack F; Ritchie M; Sapra P
    Semin Oncol; 2014 Oct; 41(5):637-52. PubMed ID: 25440608
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospects and progress of antibody-drug conjugates in solid tumor therapies.
    Govindan SV; Sharkey RM; Goldenberg DM
    Expert Opin Biol Ther; 2016 Jul; 16(7):883-93. PubMed ID: 27045979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody-drug conjugates: Current status and future perspectives.
    Gébleux R; Casi G
    Pharmacol Ther; 2016 Nov; 167():48-59. PubMed ID: 27492898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent Advances in Site Specific Conjugations of Antibody Drug Conjugates (ADCs).
    Gao W; Zhang J; Xiang J; Zhang L; Wu C; Dhal PK; Chen B
    Curr Cancer Drug Targets; 2016; 16(6):469-79. PubMed ID: 27174056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rearranging the domain order of a diabody-based IgG-like bispecific antibody enhances its antitumor activity and improves its degradation resistance and pharmacokinetics.
    Asano R; Shimomura I; Konno S; Ito A; Masakari Y; Orimo R; Taki S; Arai K; Ogata H; Okada M; Furumoto S; Onitsuka M; Omasa T; Hayashi H; Katayose Y; Unno M; Kudo T; Umetsu M; Kumagai I
    MAbs; 2014; 6(5):1243-54. PubMed ID: 25517309
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Americas Antibody Congress 2009. 21-23 September 2009, Washington DC, USA.
    Reyes CL
    IDrugs; 2009 Nov; 12(11):692-4. PubMed ID: 19844854
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Practical considerations for the pharmacokinetic and immunogenic assessment of antibody-drug conjugates.
    Sauerborn M; van Dongen W
    BioDrugs; 2014 Aug; 28(4):383-91. PubMed ID: 24842227
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bispecific Antibodies and Antibody-Drug Conjugates for Cancer Therapy: Technological Considerations.
    Shim H
    Biomolecules; 2020 Feb; 10(3):. PubMed ID: 32111076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody-targeted drugs and drug resistance--challenges and solutions.
    Shefet-Carasso L; Benhar I
    Drug Resist Updat; 2015 Jan; 18():36-46. PubMed ID: 25476546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody-Drug Conjugates as Cancer Therapeutics: Past, Present, and Future.
    Vezina HE; Cotreau M; Han TH; Gupta M
    J Clin Pharmacol; 2017 Oct; 57 Suppl 10():S11-S25. PubMed ID: 28921650
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bispecifics and antibody-drug conjugates: A positive synergy.
    Maruani A
    Drug Discov Today Technol; 2018 Dec; 30():55-61. PubMed ID: 30553521
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging new therapeutic antibody derivatives for cancer treatment.
    Jin S; Sun Y; Liang X; Gu X; Ning J; Xu Y; Chen S; Pan L
    Signal Transduct Target Ther; 2022 Feb; 7(1):39. PubMed ID: 35132063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current strategies in antibody engineering: Fc engineering and pH-dependent antigen binding, bispecific antibodies and antibody drug conjugates.
    Vincent KJ; Zurini M
    Biotechnol J; 2012 Dec; 7(12):1444-50. PubMed ID: 23125076
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity of antibody drug conjugates: bioanalytical methods and monitoring strategy for a novel therapeutic modality.
    Hock MB; Thudium KE; Carrasco-Triguero M; Schwabe NF
    AAPS J; 2015 Jan; 17(1):35-43. PubMed ID: 25380723
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibody drug conjugates under investigation in phase I and phase II clinical trials for gastrointestinal cancer.
    Leal AD; Krishnamurthy A; Head L; Messersmith WA
    Expert Opin Investig Drugs; 2018 Nov; 27(11):901-916. PubMed ID: 30359534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alternative molecular formats and therapeutic applications for bispecific antibodies.
    Spiess C; Zhai Q; Carter PJ
    Mol Immunol; 2015 Oct; 67(2 Pt A):95-106. PubMed ID: 25637431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody drug conjugates.
    Teicher BA
    Curr Opin Oncol; 2014 Sep; 26(5):476-83. PubMed ID: 25024051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.